Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Operating Leases (2021 - 2026)

Organogenesis Holdings has reported Operating Leases over the past 5 years, most recently at $22.5 million for Q4 2025.

  • For Q4 2025, Operating Leases fell 10.83% year-over-year to $22.5 million; the TTM value through Dec 2025 reached $22.5 million, down 10.83%, while the annual FY2025 figure was $22.5 million, 10.83% down from the prior year.
  • Operating Leases for Q4 2025 was $22.5 million at Organogenesis Holdings, down from $23.5 million in the prior quarter.
  • Over five years, Operating Leases peaked at $57.1 million in Q1 2021 and troughed at $20.9 million in Q4 2022.
  • A 5-year average of $32.1 million and a median of $25.1 million in 2023 define the central range for Operating Leases.
  • On a YoY basis, Operating Leases climbed as much as 80.4% in 2022 and fell as far as 55.33% in 2022.
  • Year by year, Operating Leases stood at $46.9 million in 2021, then crashed by 55.33% to $20.9 million in 2022, then grew by 19.6% to $25.1 million in 2023, then increased by 0.58% to $25.2 million in 2024, then dropped by 10.83% to $22.5 million in 2025.
  • Business Quant data shows Operating Leases for ORGO at $22.5 million in Q4 2025, $23.5 million in Q3 2025, and $24.6 million in Q2 2025.